NDAQ:INM - Post Discussion
Post by
lbell on Jun 17, 2021 9:43pm
Breakthrough Research Demonstrates Significant Uptake of CBD
I'm not flogging Zeliria but this news release could be significant for InMed once CBD/CBN treatments are approved by the US government an/or the FDA. Three of my relatives died of brain cancer - it's an ugly death.
ASX Release
Breakthrough Research Demonstrates Significant Uptake of CBD Into the Brain 18 June 2021
-
Researchers from Curtin University and funded by Zelira have developed oral capsules containing cannabidiol (CBD) that penetrated the brain faster in mice models of neurological disease.
-
The researchers developed tiny oral capsules that improved delivery of CBD into the brain by up to 40-times.
-
Data has been published in PLOS ONE, a leading peer reviewed journal.
-
Technology utilised, protected by Zelira owned patent, supports development of CBD-based treatments for a range of neurological disorders including Alzheimer’s disease, multiple
sclerosis, and traumatic brain injuries.
-
Continues Zelira’s expansion of its intellectual property portfolio and reputation for focusing
on scientific and clinically validated formulations.
-
Currently exploring potential for human studies as the next step
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global biopharmaceutical company developing and marketing cannabinoid-based medicines, is pleased to announce that a Zelira-funded team of researchers at Curtin University (Australia) have developed a new technology that improves delivery of cannabidiol (CBD) based drugs into the brains of mice by up to 40-times. This technology has potential for cannabinoid-based therapies to treat neurological disorders such as Alzheimer’s disease, multiple sclerosis, and traumatic brain injury.
Published in the leading peer reviewed open access scientific journal PLOS ONE, the Curtin University research team created tiny capsules containing cannabinoids which, when taken orally, were absorbed by the body faster and penetrated the brain quicker in mice models with neurological diseases, than when delivered in liquid form.
Lead researcher, Associate Professor Ryu Takechi from the Curtin Health Innovation Research Institute (CHIRI) and the School of Population Health, said there has been a growing interest in the use of CBD to treat various neurological diseases, but there were limitations due to its poor absorption and sensitivity to light and stomach acid when consumed orally.
“With this new capsulated form, we were able to improve the brain delivery of CBD remarkably by 40 times in animal models and we were also able to protect the drug from oxidation and degradation by light, which helps extend product shelf-life.”
“CBD is found in medicinal cannabis and is a popular natural remedy for people living with neurological and metabolic diseases. In an effort to address the issue of limitations in absorption of cannabidiol, we aimed to design and test a new drug delivery method,” Associate Professor Takechi said.
Associate Professor Takechi said “the findings may be helpful in supporting the clinical use of medicinal cannabis in the treatment of neurological disorders.”
Dr Oludare Odumosu, Zelira’s CEO said “We are delighted with the outcome of our collaboration with Dr. Takechi and his research team at Curtin University. The new encapsulation technology significantly improves the efficiency with which cannabinoid-based drugs can be delivered into the brain and presents a game changing platform to improve the effectiveness of cannabinoid therapies for neurological disorders while reducing cost and enhancing safety. This development further affirms Zelira’s commitment to innovation and leadership in cannabinoid medicine development. Associate Professor Takechi and his team are currently using the encapsulation technology to assess the efficacy of CBD to protect from and prevent cognitive decline in a mouse model of diabetes. Results will be reported later in 2021.”
This research was a collaborative effort involving researchers from CHIRI, the Curtin Medical School and the School of Population Health at Curtin University, the University of Newcastle and the University of Otago.
The full paper titled, “Sodium alginate microencapsulation improves the short-term oral bioavailability of cannabidiol when administered with deoxycholic acid,” can be found online here1.
This announcement has been approved and authorised for release by the board of Zelira Therapeutics Limited.
Oludare Odumosu Managing Director USA
Be the first to comment on this post